Overexpression of HOXD8 inhibits the proliferation, migration and invasion of breast cancer cells by downregulating ILP2 expression

Wen,Xiaoyun; Chen,Yu; Fang,Xiansong

doi:10.3892/etm.2021.10439

Overexpression of HOXD8 inhibits the proliferation, migration and invasion of breast cancer cells by downregulating ILP2 expression

Authors:
- Xiaoyun Wen
- Yu Chen
- Xiansong Fang
View Affiliations

Affiliations: Department of Clinical Laboratory, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China, Department of Blood Transfusion, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China
Published online on: July 15, 2021 https://doi.org/10.3892/etm.2021.10439
Article Number: 1006
Copyright: © Wen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most common malignant tumors in women. Although a number of homeobox (HOX) genes are known to serve an important role in breast cancer, the role of HOXD8 in breast cancer remains unclear. The aim of the present study was to investigate the role of HOXD8 in the physiological behaviors of breast cancer cells. The Gene Expression Profiling Interactive Analysis database was used to analyze the expression of HOXD8 in patients with breast cancer and in healthy subjects. Western blotting was performed to determine the expression levels of HOXD8 in several breast cancer cell lines; subsequently, HOXD8 expression was knocked down and overexpressed in MCF‑7 cells. Cell Counting Kit‑8, colony formation, wound healing and Transwell assays were used to evaluate the effects of HOXD8 on breast cancer cell viability, proliferation, migration and invasion, respectively. Chromatin immunoprecipitation and dual‑luciferase reporter assays were conducted to identify the binding sites between HOXD8 and inhibitor of apoptosis‑like protein‑2 (ILP2). In addition, ILP2 expression levels were knocked down in MCF‑7 cells. The results demonstrated that the expression levels of HOXD8 were significantly downregulated in breast cancer tissues and cell lines, and that the overexpression of HOXD8 inhibited the proliferation, invasion and migration of cancer cells. HOXD8 was shown to bind to the ILP2 promoter to regulate the expression of ILP2. Furthermore, ILP2 knockdown reversed the effects of HOXD8 knockdown on breast cancer cell proliferation, invasion and migration. In conclusion, the findings of the present study suggested that HOXD8 may inhibit the proliferation, migration and invasion of breast cancer cells by downregulating ILP2 expression.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
2	Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019.PubMed/NCBI View Article : Google Scholar
3	Peart O: Metastatic breast cancer. Radiol Technol. 88:519M–539M. 2017.PubMed/NCBI
4	Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, et al: Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol. 21:4292–4301. 2001.PubMed/NCBI View Article : Google Scholar
5	Xiang M, Zhou W, Gao D, Fang X and Liu Q: Inhibitor of apoptosis protein-like protein-2 as a novel serological biomarker for breast cancer. Int J Mol Sci. 13:16737–16750. 2012.PubMed/NCBI View Article : Google Scholar
6	Lambert M, Jambon S, Depauw S and David-Cordonnier MH: Targeting transcription factors for cancer treatment. Molecules. 23(1479)2018.PubMed/NCBI View Article : Google Scholar
7	Bemer M, van Dijk ADJ, Immink RGH and Angenent GC: Cross-family transcription factor interactions: An additional layer of gene regulation. Trends Plant Sci. 22:66–80. 2017.PubMed/NCBI View Article : Google Scholar
8	Bushweller JH: Targeting transcription factors in cancer-from undruggable to reality. Nat Rev Cancer. 19:611–624. 2019.PubMed/NCBI View Article : Google Scholar
9	Brotto DB, Siena ADD, de B II, Carvalho SDCES, Muys BR, Goedert L, Cardoso C, Plaça JR, Ramão A, Squire JA, et al: Contributions of HOX genes to cancer hallmarks: Enrichment pathway analysis and review. Tumour Biol. 42(1010428320918050)2020.PubMed/NCBI View Article : Google Scholar
10	Mansour MA and Senga T: HOXD8 exerts a tumor-suppressing role in colorectal cancer as an apoptotic inducer. Int J Biochem Cell Biol. 88:1–13. 2017.PubMed/NCBI View Article : Google Scholar
11	Sun P, Song Y, Liu D, Liu G, Mao X, Dong B, Braicu EI and Sehouli J: Potential role of the HOXD8 transcription factor in cisplatin resistance and tumour metastasis in advanced epithelial ovarian cancer. Sci Rep. 8(13483)2018.PubMed/NCBI View Article : Google Scholar
12	Liu Y, Miao L, Ni R, Zhang H, Li L, Wang X, Li X and Wang J: microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer. Oncol Rep. 36:3529–3535. 2016.PubMed/NCBI View Article : Google Scholar
13	Zhu W, Wang JP, Meng QZ, Zhu F and Hao XF: MiR-142-5p reverses the resistance to gefitinib through targeting HOXD8 in lung cancer cells. Eur Rev Med Pharmacol Sci. 24:4306–4313. 2020.PubMed/NCBI View Article : Google Scholar
14	Sun S, Wang N, Sun Z, Wang X and Cui H: MiR-5692a promotes proliferation and inhibits apoptosis by targeting HOXD8 in hepatocellular carcinoma. J BUON. 24:178–186. 2019.PubMed/NCBI
15	Zhao W, Geng D, Li S, Chen Z and Sun M: LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. Cancer Med. 7:842–855. 2018.PubMed/NCBI View Article : Google Scholar
16	Tang Z, Li C, Kang B, Gao G, Li C and Zhang Z: GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic acids research. 45:W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
17	Wei HC: Mathematical modeling of tumor growth: The MCF-7 breast cancer cell line. Math Biosci Eng. 16:6512–6535. 2019.PubMed/NCBI View Article : Google Scholar
18	Jabłońska-Trypuć A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl 1):177–183. 2016.PubMed/NCBI View Article : Google Scholar
19	Avădanei R, Căruntu ID, Amălinei C, Lozneanu L, Balan R, Grigoraş A, Ciobanu Apostol D and Giuşcă SE: High variability in MMP2/TIMP2 and MMP9/TIMP1 expression in secondary liver tumors. Rom J Morphol Embryol. 54:479–485. 2013.PubMed/NCBI
20	Kalhori V and Törnquist K: MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells. Mol Cell Endocrinol. 404:113–122. 2015.PubMed/NCBI View Article : Google Scholar
21	Sokołowska J and Urbańska K: Immunohistochemical assessment of metalloproteinases MMP2 and MMP9 expression in canine various subtypes of lymphomas in relation with proliferative and apoptotic markers. Pol J Vet Sci. 22:203–211. 2019.PubMed/NCBI View Article : Google Scholar
22	Wang X, Yang B, She Y and Ye Y: The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9. J Cell Biochem. 119:7790–7799. 2018.PubMed/NCBI View Article : Google Scholar
23	Varfolomeev E and Vucic D: Inhibitor of apoptosis proteins: Fascinating biology leads to attractive tumor therapeutic targets. Future Oncol. 7:633–648. 2011.PubMed/NCBI View Article : Google Scholar
24	Fulda S: Exploiting inhibitor of apoptosis proteins as therapeutic targets in hematological malignancies. Leukemia. 26:1155–1165. 2012.PubMed/NCBI View Article : Google Scholar
25	Fulda S: Inhibitor of apoptosis proteins as targets for anticancer therapy. Expert Rev Anticancer Ther. 7:1255–1264. 2007.PubMed/NCBI View Article : Google Scholar
26	Zhu L, Zhou W, Zhu X, Xiang S, Wang S, Peng Y, Lu B, Tang P, Chen Q, Wu M, et al: Inhibitor of apoptosis protein-like protein-2: A novel growth accelerator for breast cancer cells. Oncol Rep. 40:2047–2055. 2018.PubMed/NCBI View Article : Google Scholar
27	Khalili S, Mohammadpour H, Shokrollahi Barough M and Kokhaei P: ILP-2 modeling and virtual screening of an FDA-approved library: A possible anticancer therapy. Turk J Med Sci. 46:1135–1143. 2016.PubMed/NCBI View Article : Google Scholar